Opus Genetics raises ~$23M in registered direct offering with Perceptive, Nantahala, Balyasny

Opus Genetics, Inc.

Purchase agreement with affiliates of Perceptive, Nantahala, and Balyasny for 3.83M shares and 7.18M pre-funded warrants at $2.09/$2.0899.
Gross proceeds ~$23M; net proceeds to advance LCA5 and BEST-1 gene therapy programs and for working capital.
Pre-funded warrants exercisable at $0.0001/share, subject to 4.99%/9.99% beneficial ownership limitation.
Closing expected November 7, 2025; no placement agent or underwriting discounts.
Offering registered on Form S-3; customary closing conditions remain.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.